Medicure Inc (MCUJF) 2.5384 $MCUJF
Medicure Provides Update on Tardoxal and TEND-TD Study
Marketwire - Wed Aug 13, 11:23AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, announces that the preliminary results of its Phase IIa Clinical Trial, Tardoxal(TM) for the Treatment of Tardive Dyskinesia (TEND-TD) showed a non-statistically significant improvement in the primary efficacy endpoint in patients treated with Tardoxal. Medicure views these preliminary results as supportive of continuing the program and developing a modified formulation as a prelude to a larger, confirmatory Phase II study.
Medicure Announces Shares for Debt Settlement
Marketwire - Fri Jul 11, 1:59PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation.
Medicure Announces Grant of Options
Marketwire - Mon Jul 07, 3:31PM CDT
Medicure Inc. (the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 332,300 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 92,300 are set to expire on the tenth anniversary of the date of grant, and 240,000 are set to expire on the fifth anniversary of the date of grant. All 332,300 options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange.
Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore
Marketwire - Thu Jul 03, 7:38AM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA" have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest" in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3 years. The Ownership Interest and certain other rights, including the Option Rights described below, were obtained by Medicure for its lead role in structuring a US$22.5 million, majority interest purchase and financing of Apicore (the "Purchase" by Signet Healthcare Partners ("Signet" , Knight Therapeutics Inc. (TSX: GUD) ("Knight" , and investors affiliated with Sanders Morris Harris Inc. ("Sanders" (collectively, the "Investors" .
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
Marketwire - Thu Jul 03, 7:21AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" , a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. The purchase arrangement included a secured loan provided by Knight and Sanders Morris Harris Inc., and an equity investment by Signet Healthcare Partners ("Signet" for an aggregate amount of US$22.5 million. Medicure Inc. ("Medicure" acquired a minority interest in Apicore and the founding shareholders of Apicore continue to own a significant minority interest in Apicore.
Medicure Reports Financial Results for the Third Quarter Fiscal 2014
Marketwire Canada - Wed Mar 26, 4:11PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE:MPH) (OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014.
Medicure Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 4:00AM CDT
Summary
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company" (TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013.
Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Medicure Provides Update on Tardoxal and TEND-TD Study
Marketwire - Wed Aug 13, 11:23AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, announces that the preliminary results of its Phase IIa Clinical Trial, Tardoxal(TM) for the Treatment of Tardive Dyskinesia (TEND-TD) showed a non-statistically significant improvement in the primary efficacy endpoint in patients treated with Tardoxal. Medicure views these preliminary results as supportive of continuing the program and developing a modified formulation as a prelude to a larger, confirmatory Phase II study. Medicure Announces Shares for Debt Settlement
Marketwire - Fri Jul 11, 1:59PM CDT
Medicure Inc. (the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that the Company, subject to all necessary regulatory approvals, has entered into shares for debt agreements with its Chief Executive Officer, Dr. Albert Friesen and certain members of the Board of Directors, pursuant to which the Company will issue 205,867 of its common shares at a deemed price of $1.98 per common share to satisfy $407,616.66 of outstanding amounts owing to Dr. Friesen and members of the Company's Board of Directors. These shares will be subject to resale restrictions for a period of four months from the date of issuance under applicable securities legislation. Medicure Announces Grant of Options
Marketwire - Mon Jul 07, 3:31PM CDT
Medicure Inc. (the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 332,300 options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to the Company's Stock Option Plan. Of these options, 92,300 are set to expire on the tenth anniversary of the date of grant, and 240,000 are set to expire on the fifth anniversary of the date of grant. All 332,300 options were issued at an exercise price of $1.90 per share. The options are subject to the approval of the TSX Venture Exchange. Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore
Marketwire - Thu Jul 03, 7:38AM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today announced that the Company and its newly formed and wholly owned subsidiary, Medicure U.S.A. Inc. ("Medicure USA" have entered into an arrangement whereby they have acquired a minority interest in a pharmaceutical manufacturing business. Specifically, Medicure and Medicure USA have acquired a 6.09% equity interest (5.33% on a fully-diluted basis) (the "Ownership Interest" in two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3 years. The Ownership Interest and certain other rights, including the Option Rights described below, were obtained by Medicure for its lead role in structuring a US$22.5 million, majority interest purchase and financing of Apicore (the "Purchase" by Signet Healthcare Partners ("Signet" , Knight Therapeutics Inc. (TSX: GUD) ("Knight" , and investors affiliated with Sanders Morris Harris Inc. ("Sanders" (collectively, the "Investors" . Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
Marketwire - Thu Jul 03, 7:21AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, "Apicore" will be wholly owned operating subsidiaries. The purchase arrangement included a secured loan provided by Knight and Sanders Morris Harris Inc., and an equity investment by Signet Healthcare Partners ("Signet" for an aggregate amount of US$22.5 million. Medicure Inc. ("Medicure" acquired a minority interest in Apicore and the founding shareholders of Apicore continue to own a significant minority interest in Apicore. Medicure Reports Financial Results for the Third Quarter Fiscal 2014
Marketwire Canada - Wed Mar 26, 4:11PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE:MPH) (OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended February 28, 2014. Medicure Inc. - Product Pipeline Review - 2013
M2 - Tue Mar 18, 4:00AM CDT
Summary
Innovative Food Holdings, Inc. Presents at MicroCapClub Invitational
Marketwire - Tue Feb 04, 7:45AM CST
Innovative Food Holdings, Inc. (OTCQB: IVFH) announced today it has been selected to present at the 2nd annual MicroCapClub Invitational.
Medicure Reports Second Quarter Financial Results for Fiscal 2014
Marketwire - Tue Jan 28, 3:31PM CST
Medicure Inc. ("Medicure" or the "Company"
(TSX VENTURE: MPH)(OTCQB: MCUJF), a specialty pharmaceutical company, today reported its results from operations for the second quarter ended November 30, 2013. Beer in Hungary
M2 - Wed Jan 22, 3:28AM CST
After a difficult period for the beer industry in Hungary caused by the negative effects of the economic crisis on consumer purchasing power, the decline in beer consumption started to turn around in 2011 and in 2012, beer sales continued to grow in both value and volume terms. Volume sales surpassed 700 million litres, but this is still a long way from the volume sales of five years ago. Due to stable demand by beer consumers further recovery is expected.
Beer in India
M2 - Wed Jan 22, 3:28AM CST
Beer sales posted a growth of 11% in terms of total volume, spurred by a hot summer of 2012 and rising prices of competing liquor like spirits and wine. In addition, a crackdown by state governments on illegal spirits and country liquor also caused a shift to branded beer.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
